577 related articles for article (PubMed ID: 22471664)
41. Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.
Backer MV; Hamby CV; Backer JM
Adv Genet; 2009; 67():1-27. PubMed ID: 19914448
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor as a therapeutic target in cancer.
Bergsland EK
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
[TBL] [Abstract][Full Text] [Related]
43. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
44. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
45. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Frumovitz M; Sood AK
Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
[TBL] [Abstract][Full Text] [Related]
46. VEGF kinase inhibitors: how do they cause hypertension?
Bhargava P
Am J Physiol Regul Integr Comp Physiol; 2009 Jul; 297(1):R1-5. PubMed ID: 19439616
[TBL] [Abstract][Full Text] [Related]
47. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
48. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
50. Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression.
Bzowska M; Mężyk-Kopeć R; Próchnicki T; Kulesza M; Klaus T; Bereta J
Acta Biochim Pol; 2013; 60(3):263-75. PubMed ID: 23819129
[TBL] [Abstract][Full Text] [Related]
51. [Tumor angiogenesis: recent progress and remaining challenges].
Feige JJ
Bull Cancer; 2010 Nov; 97(11):1305-10. PubMed ID: 21051315
[TBL] [Abstract][Full Text] [Related]
52. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
53. The function of vascular endothelial growth factor.
Nieves BJ; D'Amore PA; Bryan BA
Biofactors; 2009; 35(4):332-7. PubMed ID: 19415738
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic therapy for high-grade gliomas.
Chamberlain MC; Raizer J
CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):184-94. PubMed ID: 19601816
[TBL] [Abstract][Full Text] [Related]
55. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
56. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
58. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
59. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
60. Antiangiogenesis, anti-VEGF(R) and outlook.
Petersen I
Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]